{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:01:51Z","timestamp":1759449711780,"version":"build-2065373602"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n               Background Chorioretinopathy centralis serosa (CCS) is a common disease that leads to the loss of retinal ion\/fluid homeostasis due to decompensation of the retinal pigment epithelium, resulting in fluid accumulation with detachment of the neurosensory retina and\/or retinal pigment epithelium. We investigated the effect of eplerenone, a mineralocorticoid receptor inhibitor, on chronic recurrent CCS (cr-CCS).<\/jats:p><jats:p>\n               Methods A retrospective study with data analysis of 17 eyes (12 patients) between 2014\u200a\u2013\u200a2021 with cr-CCS in whom other methods were not effective, not applicable, or not desired, was performed. Duration of CCS was at least 12 months with at least one recurrence. Each patient received 25\u2009mg (1st week) and 50\u2009mg (from the 2nd week) for at least 3 months. In each case, best-corrected visual acuity and central and peripheral retinal thickness were measured by spectral-domain optical coherence tomography. Side effects were rated by the patients as \u201cnone\u201d, \u201cmild\u201d (noticeable but not affecting), \u201ctolerable\u201d (affecting but acceptable because of good effect), and \u201cnot tolerable\u201d (then discontinuation of therapy).<\/jats:p><jats:p>\n               Results There was no significant reduction in central or peripheral retinal thickness. A complete reduction of subretinal fluid was achieved in 5 of 17 eyes (29.4%). In 12 eyes, no effect of eplerenone could be detected, so other therapies were required. Visual acuity change was mainly dependent on the duration of CCS and the degree of photoreceptor damage. Side effects were reported by 11 patients as \u201cnone\u201d and 1 patient as \u201cmild\u201d (arterial hypotension). No other side effects were observed.<\/jats:p><jats:p>\n               Conclusion The response rates of therapy with eplerenone were relatively low, and no significant effect could be demonstrated. Eplerenone should not (no longer) be routinely used in the therapy of cr-CCS.<\/jats:p>","DOI":"10.1055\/a-2105-0892","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T19:21:24Z","timestamp":1693941684000},"page":"1039-1043","source":"Crossref","is-referenced-by-count":0,"title":["Eplerenone for the Treatment of Chronic Recurrent Chorioretinopathy Centralis Serosa"],"prefix":"10.1055","volume":"241","author":[{"given":"Lisa-Marie","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Matth\u00e9","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Sandner","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dierk","family":"Wittig","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00347-021-01379-4","article-title":"Einheitliche Klassifikation des pachychorioidalen Krankheitsspektrums","volume":"118","author":"A D Abdin","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study","volume":"33","author":"E Bousquet","year":"2013","journal-title":"Retina"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000360014","article-title":"Central Serous Chorioretinopathy","volume":"232","author":"R Liegl","year":"2014","journal-title":"Ophthalmologica"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1111\/aos.14319","article-title":"An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study","volume":"98","author":"M R Romano","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment","volume":"58","author":"B Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"C MG Cheung","year":"2019","journal-title":"Eye (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bjophthalmol-2019-314047","article-title":"Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience","volume":"104","author":"D S Petkovsek","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"M Zhao","year":"2012","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid Receptor Antagonist Treatment in Bilateral Chronic Central Serous Chorioretinopathy: A Comparative Study of Exudative and Nonexudative Fellow Eyes","volume":"37","author":"R Gergely","year":"2017","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","article-title":"A Randomized Double-Blind Placebo-Control Pilot Study of Eplerenone for the Treatment of Central Serous Chorioretinopathy (ECSELSIOR)","volume":"38","author":"E Rahimy","year":"2018","journal-title":"Retina"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"A Lotery","year":"2020","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"M Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"R Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41433-019-0568-y","article-title":"Oral medications for central serous chorioretinopathy: a literature review","volume":"34","author":"W Fusi-Rubiano","year":"2020","journal-title":"Eye (Lond)"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2105-0892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:31:22Z","timestamp":1759361482000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2105-0892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":14,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2024,9,16]]},"published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2105-0892","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}